Clinicopathologic implications of tissue inhibitor of metalloproteinase-1-positive diffuse large B-cell lymphoma

Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
Jung-Woo ChoiYoung-Sik Kim

Abstract

The tissue inhibitor of metalloproteinase-1 (TIMP-1) is a stromal factor that promotes plasmablastic differentiation, and the survival of germinal center B-cells. The expression of TIMP-1 is known to be correlated with a subset of non-Hodgkin lymphoma at the mRNA level, and Epstein-Barr virus infection in vitro. To characterize TIMP-1(+) diffuse large B-cell lymphoma, TIMP-1 expression was investigated in tissue microarrays from 182 cases of de novo diffuse large B-cell lymphoma and compared with prognostic factors, immunophenotypes, and Epstein-Barr virus infection status. TIMP-1 was expressed not only in tumor cells themselves, in 14 of 182 cases (8%), designated as TIMP-1(+) diffuse large B-cell lymphoma, but also in stromal cells like fibroblasts and endothelial cells. In univariate analysis and hierarchical clustering, our findings suggest that TIMP-1 expression may represent a distinct subgroup. In multivariate analysis, TIMP-1(+) diffuse large B-cell lymphoma (n=14) was associated with unfavorable outcomes compared to TIMP-1(-) diffuse large B-cell lymphoma (n=168) (odds ratio=2.5, P=0.049). Together with TIMP-1 expression, age (greater than 60 years), the presence of B-symptoms, abnormal lactate dehydrogenase level, or ...Continue Reading

References

Jan 1, 1997·Kidney & Blood Pressure Research·M E Safar, G M London
Dec 3, 1998·The Journal of Clinical Investigation·L GuedezM Stetler-Stevenson
Dec 9, 1998·Proceedings of the National Academy of Sciences of the United States of America·M B EisenD Botstein
Feb 13, 1999·International Journal of Cancer. Journal International Du Cancer·K McCarthyM J Duffy
Mar 10, 2000·Biochimica Et Biophysica Acta·K BrewH Nagase
Jul 17, 2001·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Y NatkunamM van De Rijn
Sep 14, 2001·Current Opinion in Oncology·B Coiffier
Jun 21, 2002·The New England Journal of Medicine·Andreas RosenwaldUNKNOWN Lymphoma/Leukemia Molecular Profiling Project
Oct 24, 2002·Human Pathology·Cyrus V HedvatJulie Teruya-Feldstein
Dec 14, 2002·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Martha Milanes-YearsleyMilijenko Pilepich
Sep 26, 2003·American Journal of Hematology·Michael B MøllerBjarne E Christensen
Oct 31, 2003·Trends in Genetics : TIG·Yuk Fai Leung, Duccio Cavalieri
Nov 14, 2003·Oncogene·Li-Teh LiuWen-Chun Hung
Dec 4, 2003·Biochemical and Biophysical Research Communications·Seo-Jin LeeSeung-Taek Lee
Feb 14, 2004·European Journal of Haematology·Heli PennanenTaina Turpeenniemi-Hujanen
Mar 24, 2004·Critical Reviews in Oncology/hematology·Elise LambertEmmanuelle Petitfrère
Apr 10, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Anne-Sofie SchrohlJohn A Foekens
Jun 25, 2004·Experimental and Molecular Pathology·Minalini LakshmanSerge Jothy
May 28, 2005·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Christine P HansJames O Armitage
Aug 6, 2005·Biochemical and Biophysical Research Communications·Fu-Chuan HsiehJiayuh Lin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.